Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2025 Filed Dec 4, 2025 18:46 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $251.47 | $502,940.00 |
DisclosureSEC source: 0000943819-25-000186 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:27 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 50 | $244.16 | $12,208.00 |
DisclosureSEC source: 0000943819-25-000185 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,791 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:23 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $244.16 | $244,160.00 |
DisclosureSEC source: 0000943819-25-000184 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 19:40 UTC |
De Witte JanDirector
|
SaleReMed Common Stock | 2,055 | $255.00 | $524,025.00 |
DisclosureSEC source: 0000943819-25-000181 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,261 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 20:29 UTC |
Farrell Michael J.Director · Chairman and CEO
|
GrantResMed Common Stock Options · Derivative | 33,288 | $250.52 Strike: $250.52 | $8,339,309.76 |
DisclosureSEC source: 0000943819-25-000183 · form4.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,288 Underlying: ResMed Common Stock · 33,288 shares Expires 2032-11-11 F1 · derivative.exercise_date: Represents the date on which options first become exercisable. The options vest in three equal annual installments commencing on November 11, 2026. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 20:26 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock Options · Derivative | 1,331 | $250.52 Strike: $250.52 | $333,442.12 |
DisclosureSEC source: 0000943819-25-000182 · form4.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,331 Underlying: ResMed Common Stock · 1,331 shares Expires 2032-11-11 F1 · derivative.exercise_date: Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 17:29 UTC |
Mowad-Nassar NicoleDirector
|
GrantResMed Common Stock Options · Derivative | 1,331 | $250.52 Strike: $250.52 | $333,442.12 |
DisclosureSEC source: 0000943819-25-000180 · form4.xml · derivative · entry 2 Mowad-Nassar Nicole · CIK 0002084190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,331 Underlying: ResMed Common Stock · 1,331 shares Expires 2032-11-11 F1 · derivative.exercise_date: Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 20:28 UTC |
Leong JustinChief Product Officer
|
GrantReMed Common Stock | 1,848 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000179 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,028 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 19:42 UTC |
Mowad-Nassar NicoleDirector
|
GrantResMed Common Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000177 · form4.xml · nonDerivative · entry 1 Mowad-Nassar Nicole · CIK 0002084190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 20:26 UTC |
Hernandez JohnDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000178 · form4.xml · nonDerivative · entry 1 Hernandez John · CIK 0001890555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,118 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 16:20 UTC |
Tan DesneyDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000176 · form4.xml · nonDerivative · entry 1 Tan Desney · CIK 0001890548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,002 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 16:12 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000175 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,940 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 16:09 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000174 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,602 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 16:06 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000173 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,156 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:45 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 2,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000171 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,495 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:49 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000172 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,771 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:42 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Tax withholdingResMed Common Stock | 7,297 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000170 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,223 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on November 16, 2022. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:42 UTC |
Farrell Michael J.Director · Chairman and CEO
|
GrantResMed Common Stock | 13,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000170 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,520 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:49 UTC |
DelOrefice ChristopherDirector
|
GrantResMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000167 · form4.xml · nonDerivative · entry 1 DelOrefice Christopher · CIK 0001881430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,423 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:39 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000164 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,773 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:45 UTC |
De Witte JanDirector
|
GrantReMed Common Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000166 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,316 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 11,442 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000122 · form4.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 11,442 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:59 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 7,314 | $244.46 | $1,787,980.44 |
DisclosureSEC source: 0000943819-25-000122 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,238 F2 · kind: Disposition to issuer for tax withholding and cost to exercise the options granted on 11/14/2018. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 11,442 | $101.64 | $1,162,964.88 |
DisclosureSEC source: 0000943819-25-000122 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction represents Options automatically exercised pursuant to the award terms. Options are vested in full. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 22:39 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $252.05 | $504,100.00 |
DisclosureSEC source: 0000943819-25-000117 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,110 F2 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:37 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Tax withholdingResMed Common Stock | 2,205.697 | $250.10 | $551,644.82 |
DisclosureSEC source: 0000943819-25-000116 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,969 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:37 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Tax withholdingResMed Common Stock | 3,459.325 | $250.10 | $865,177.18 |
DisclosureSEC source: 0000943819-25-000116 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,175 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:37 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Tax withholdingResMed Common Stock | 2,231.545 | $250.10 | $558,109.40 |
DisclosureSEC source: 0000943819-25-000116 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,634 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:39 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 162.953 | $250.10 | $40,754.55 |
DisclosureSEC source: 0000943819-25-000117 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,110 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:24 UTC |
De Witte JanDirector
|
Tax withholdingReMed Common Stock | 76.449 | $250.10 | $19,119.89 |
DisclosureSEC source: 0000943819-25-000115 · form4.xml · nonDerivative · entry 2 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,242 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:24 UTC |
De Witte JanDirector
|
SaleReMed Common Stock | 487 | $250.25 | $121,871.75 |
DisclosureSEC source: 0000943819-25-000115 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,319 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted Feb 03, 2025. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:23 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 500.735 | $250.10 | $125,233.82 |
DisclosureSEC source: 0000943819-25-000096 · form4.xml · nonDerivative · entry 4 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,841 F5 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:23 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 715.489 | $250.10 | $178,943.80 |
DisclosureSEC source: 0000943819-25-000096 · form4.xml · nonDerivative · entry 3 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,342 F4 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:23 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 173.725 | $250.10 | $43,448.62 |
DisclosureSEC source: 0000943819-25-000096 · form4.xml · nonDerivative · entry 2 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,057 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:23 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 135.075 | $250.10 | $33,782.26 |
DisclosureSEC source: 0000943819-25-000096 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,231 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. F2 · balance_after: Includes 38.9396 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 14:13 UTC |
Gill HarjitDirector
|
Tax withholdingResMed Common Stock | 38.209 | $250.10 | $9,556.07 |
DisclosureSEC source: 0000943819-25-000119 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,867 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 7,028 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · derivative · entry 6 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 7,028 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 983 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,028 Underlying: ResMed Common Stock · 983 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 8,011 | $249.75 | $2,000,772.89 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,866 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 7,028 | $101.64 | $714,325.92 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 983 | $101.64 | $99,912.12 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 468,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · balance_after: Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000092 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 2,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $247.54 | $742,620.00 |
DisclosureSEC source: 0000943819-25-000092 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,745 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:02 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,000 | $101.64 | $203,280.00 |
DisclosureSEC source: 0000943819-25-000092 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 15:03 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000086 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,011 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 15:03 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 8,009 | $282.85 | $2,265,332.03 |
DisclosureSEC source: 0000943819-25-000086 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,792 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $280.95 - $283.90. The price reported above reflects the weighted average sale price. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 15:03 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0000943819-25-000086 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:32 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 100 | $274.36 | $27,436.00 |
DisclosureSEC source: 0000943819-25-000080 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,327 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 16:56 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000084 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Underlying: ResMed Common Stock · 2,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 16:56 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $274.36 | $823,080.00 |
DisclosureSEC source: 0000943819-25-000084 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,745 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.